MERUS N.V. EO -09 (2GH F) stock market data APIs
€35.7428
0(0%)
as of May 12, 2025
Try our APIs with
free plan!
MERUS N.V. EO -09 Financial Data Overview
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Prev. Close
35.7428
Open
35.7428
High
35.7249
Low
35.7428
52 wk Range
29.4-55.5
Market Cap
2 609 M
Shares Outstanding
69 183 K
Revenue
36 133 K
Beta
0.948
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MERUS N.V. EO -09 data using free add-ons & libraries
Get MERUS N.V. EO -09 Fundamental Data
MERUS N.V. EO -09 Fundamental data includes:
- Net Revenue: 36 133 K
- EBITDA: -269 596 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MERUS N.V. EO -09 News
New
Merus First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Merus (NASDAQ:MRUS) First Quarter 2025 Results Key Financial Results Revenue: US$26.5m (up 236% from 1Q 2024). Net loss: US$96.5m (loss widened by 180% from 1Q 2024). US$1.40 loss per share (further...
Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain
We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Merus N.V. (NASDAQ:MRUS) stands against other best cancer ...
Merus to Present at BofA Securities 2025 Health Care Conference
Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (...
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $0.59 per share a year ago. These figures are adjus...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
